Gedeon Richter’s sales revenues for Q1-Q3 2018 affected by fall in Esmya sales and poor performance of Romanian wholesale and retail

Justyna Zagórska, Pharmaceutical Market Analyst
The consolidated sales revenues of Gedeon Richter, the prominent Hungarian pharmaceutical manufacturer, came to HUF 323.9bn (€1.0bn) in the first nine months of 2018, a reduction of 3.1% year on year (5.8% in euro) in comparison with the corresponding period of 2017. According to the company’s financial report, the sales performance was adversely affected by a reduction in sales of Esmya and by the limited turnover of its wholesale and retail activity in Romania. Because of the temporary restriction of Esmya sales imposed by the European Medicines Agency (EMA) Pharmacovigilance Risk…

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.